Novel strategies exploiting interleukin-12 in cancer immunotherapy.
Adoptive T cell therapy
And RNA-mediated delivery
Expression plasmids
Fusion proteins
Interleukin-12
Localized delivery
Viral vectors
Journal
Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
05
01
2022
revised:
05
04
2022
accepted:
11
04
2022
pubmed:
18
4
2022
medline:
9
11
2022
entrez:
17
4
2022
Statut:
ppublish
Résumé
Interleukin-12 is considered a potent agent to enhance antitumor immune responses. It belongs to a family of heterodimeric cytokines with key roles in the up-regulation and down-regulation of cellular immunity. Since its discovery, recombinant IL-12 was found to exert potent antitumor effects in rodent tumor models and was rapidly tested in the clinic with an unfavorable benefit/toxicity profile. Localized delivery of IL-12 dramatically improves the therapeutic index and this approach is being applied in the clinic based on in-vivo electroporation of naked plasmid DNA encoding IL-12, mRNA formulations, viral vectors and tumor-targeted fusion proteins. Other biotechnology strategies such as IL-12-engineered local adoptive cell therapy and pro-cytokines can also be used to improve results and broaden the therapeutic window. Combination strategies of such localized IL-12-based approaches with checkpoint inhibitors are yielding promising results both preclinically and in the early-phase clinical trials.
Identifiants
pubmed: 35430292
pii: S0163-7258(22)00083-3
doi: 10.1016/j.pharmthera.2022.108189
pii:
doi:
Substances chimiques
Interleukin-12
187348-17-0
Immunologic Factors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108189Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.